And, as usual, you slice and dice words.
Perhaps I should have said in the original message post: Daiichi isn't known for preclinical through late stage development of oncology drugs - they're more of a CV company. Hence, their description on their own website as "We currently market therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome and metastatic melanoma." (the last of which they got through acquisition - not because they developed it internally in any early stage of the development.
If I knew I was being graded on language wording here, I probably would have been more careful.
